Cosmos Health Inks Libytec Deal for Generic Januvia in Greece, But Financial Distress Remains Paramount

What happened

Cosmos Health has entered a five-year partnership with Libytec to commercialize DIABIT-IS X (sitagliptin), a generic alternative to Merck's Januvia, in Greece. Under the agreement, Cosmos will supply the product while Libytec handles distribution and promotion, with access through the national health insurance system expected to broaden reach. The deal adds a modest revenue stream and improves visibility, but it does not address the company's fundamental cash-burn problem, going-concern warnings, or reliance on dilutive financing. DeepValue's analysis highlights that all three operating segments remain loss-making, working capital is negative, and the capital structure is increasingly complex due to a $300M crypto-linked facility. This single-country, single-product partnership is unlikely to materially alter the trajectory of a company that posted a $5.4M net loss in Q3 2025 alone.

Implication

The partnership provides incremental revenue and a foothold in Greek prescription generics, but COSM remains a high-risk speculative stock. Unless management demonstrates a credible path to self-funded operations and refinances 2026 debt without severe dilution, equity holders face significant impairment. Wait for evidence of working capital improvement and reduced ATM issuance before considering entry.

Thesis delta

The Libytec agreement supports management's 'prescription medicine strategy' narrative but is too small to shift the fundamental thesis. Cosmos still lacks a viable path to profitability, faces going-concern risk, and depends on dilutive capital. The bear case (45% probability of $0.15) remains intact; the partnership does not change the expected negative skew of returns.